placebo group – Communicable Diseases Research

Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial

Article

Published on 2022-11-032022-11-16
Journal: Journal of Translational Medicine
[Category] 비임상,

Bamlanivimab Use in a Military Treatment Facility

Article

Published on 2022-10-292022-11-15
Journal: Military Medicine
[Category] COVID19(2023년), SARS, 진단,

[키워드] acute respiratory syndrome Administered administration Admission analyzed approval approved Arm bamlanivimab Care caused cohort study coronavirus coronavirus disease COVID-19 COVID-19 patient death declined diagnosed Disease progression facility FDA Follow-up Guidance help hospital Hospital admission Hospitalization information initial inpatient admission institutional review board intravenous IRB lack Mild-to-moderate monoclonal antibody Patient patients patients with SARS-CoV-2 placebo group Prevent Primary outcome progression provided receiving replicated reported required retrospective risk risk factor SARS-CoV-2 secondary outcome self-reported symptom severe COVID-19 small sample size Spread statistical significance statistically significant Study design Symptom treated Treatment treatment group virus-neutralizing was obtained were given Wuhan, China
[DOI] 10.1093/milmed/usab188 PMC 바로가기

Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19: A double-blind placebo-controlled clinical trial

Article

Published on 2022-10-012022-11-15
Journal: Phytotherapy research : PTR
[Category] COVID19(2023년), SARS, 치료제,

[키워드] alanine aminotransferase Anti-viral Antiviral assigned baseline clinical trial Concomitant COVID-19 cytokine release Cytokine release syndrome Dexamethasone dosage double-blind Effect effective Effectiveness Efficacy Evidence follow-up period gel Hospitalization hospitalized patient Laboratory Laboratory parameters lack liver enzyme management outbreak pandemic participant Patient patients with COVID-19 placebo group placebo-controlled clinical trial receiving Remdesivir sample sizes SARS-CoV-2 significant difference significantly silymarin. Symptom the placebo group therapeutic strategy Treatment treatment group two group viral disease were assessed
[DOI] 10.1002/ptr.7537 PMC 바로가기

Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

Article

Published on 2022-09-172022-10-06
Journal: EClinicalMedicine
[Category] 진단,

[키워드] 1:1 95 % CI Activation addition Administered adverse event approach assigned Basel blockade BMI canakinumab Clinical outcome contributing to COVID-19 CRP Dexamethasone diabetes died dose double-blind dropped drug Efficacy foundation glycaemic control higher risk hospitalised Hospitalization Hyperinflammatory ICU IL-1beta IL-1β IL-6 IMPROVE Inflammasome innate immune system interleukin-1β intravenous dose less medication multicenter multicentre Novartis Obesitiy. obesity outcome participant Patient patients treated patients with COVID-19 Placebo placebo group placebo-controlled trial primary analysis randomised randomization Randomly reduction Registered reported required SARS-CoV2 SARS-CoV2 infection Science Seven severe COVID-19 significantly Standard-of-care statistically significant statistically significant difference survival Switzerland systemic inflammation tested treated Treatment type 2 diabete university Ventilation with COVID-19
[DOI] 10.1016/j.eclinm.2022.101649 PMC 바로가기 [Article Type] Article

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial

Clinical Trial

Published on 2022-09-012022-10-04
Journal: International Journal of Infectious Diseases
[Category] COVID19(2023년), SARS, 임상, 치료제,

Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial

경증 COVID-19에서 입원으로의 진행을 예방하는 단일 용량 및 이중 용량 이버멕틴 조기 치료의 효능: 다군, 병렬 그룹, 무작위, 이중 맹검, 위약 대조 시험

Randomized Controlled Trial

Published on 2022-09-012022-09-11
Journal: Respirology (Carlton, Vic.)
[Category] COVID19(2023년), SARS, 임상, 치료제,

[키워드] absolute difference adverse event anti-parasitic Antiviral antiviral agent Clinical course clinical trial conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection dermatitis double-blind early treatment Efficacy enrolled evaluate Hospitalization hypertension investigated Ivermectin ivermectin group Mild mild COVID-19 mild COVID-19 patients Mild symptom mild symptoms multi-arm no significant difference parallel-group Patient Placebo placebo group placebo-controlled trial Primary outcome progression proportion proportions Randomized randomized clinical trial randomized clinical trial. receive required reverse transcription reverse transcription-PCR SARS-CoV-2 severity Severity Score Single-dose statistically significant subject Tachycardia
[DOI] 10.1111/resp.14318 PMC 바로가기 [Article Type] Randomized Controlled Trial

The short-term effect of a myofascial protocol versus light touch applied to the cervical spine towards the prevention of balance disorders in the elderly: protocol of a randomised controlled trial

Article

Published on 2022-08-312022-10-05
Journal: Chiropractic & manual therapies
[Category] SARS, 임상,

[키워드] applied balance balance disorder battery Cervical cervical spine concerning Consequences COVID demonstrated double-blind Effect effective elderly evaluator experiment experimental group Gait group Health Inclusion influence Intervention knowledge lower limb lower limbs manual Mobility muscle Myofascial Myofascial release Neck Non-invasive occur Older adults Pain pandemic parameter Patient performance physical physiological Placebo placebo group prevention protection protocol Psychological randomised controlled trial Randomized receive recruitment reduce risk spine strength Strength. subject the placebo group Therapeutic treatment therapy trauma Treatment Variability
[DOI] 10.1186/s12998-022-00446-0 PMC 바로가기 [Article Type] Article

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load

코로나19 고위험 보행 환자를 대상으로 한 밤라니비맙과 에테세비맙의 무작위 위약 대조 임상 시험 및 지속적으로 높은 바이러스 부하의 예후 가치 검증

Randomized Controlled Trial

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat
[Category] SARS, 변종, 임상, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age ambulatory ambulatory patient ambulatory patients antibody treatment applicability bamlanivimab baseline characterized clinical clinical status Cohort confidence interval coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 test Day death determine etesevimab expand first positive greater high risk Hospitalization infused Interim analyses interim analysis intravenously investigated load lower dose median median age Mild-to-moderate NCT04427501 occurred optimal dose outcome Patient persistently high viral load. phase Placebo placebo group receiving reduction in respiratory risk factor SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 Support the placebo group These data those receiving placebo Treatment Trial validation value variant Viral Viral load
[DOI] 10.1093/cid/ciab912 PMC 바로가기 [Article Type] Randomized Controlled Trial

Therapeutic ultrasound versus injection of local anesthetic in the treatment of women with chronic pelvic pain secondary to abdominal myofascial syndrome: a randomized clinical trial

Randomized Controlled Trial

Published on 2022-08-022022-10-05
Journal: BMC Women's Health
[Category] 임상,

[키워드] abdomen abdominal pain absence analyzed cause characterized chronic clinical clinical trial Comorbidity conducted continuous pain Controlled clinical trial COVID-19 CPP defined dysfunction effective Efficacy evaluate evaluated Evidence exclusion groups IMPROVE injection Local Local anesthesia material Musculoskeletal Myofascial Myofascial pain syndrome no significant difference Pain Patient Pelvic Pelvic pain placebo group Quality of life questionnaire randomized clinical trial reducing Registered registry scale Study participants syndrome Tertiary therapeutic Therapeutic ultrasound Treatment Ultrasonic therapy Ultrasonic therapy. university variable Visual women
[DOI] 10.1186/s12905-022-01910-y PMC 바로가기 [Article Type] Randomized Controlled Trial

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

알츠하이머병(NorAD)에서 연장 방출 구안파신을 사용한 노르아드레날린성 추가 요법: 무작위 임상 시험 및 COVID-19 수정안에 대한 연구 프로토콜

Article

Published on 2022-08-012022-09-11
Journal: Trials
[Category] 임상,

[키워드] activities activity Add-on therapy addition Adrenergic receptor affected Alzheimer's disease Alzheimer’s disease approved assessment Attention attention deficit baseline Brain burden cholinesterase inhibitor clinical trial Cognition cognitive Combination combination therapy COVID-19 Daily daily living determine disease disorder double-blind dysfunction evaluate Evidence executive Follow-up function Guanfacine Guanfacine. hyperactivity IMPROVE include interview inventory involved locus measure Mild mild to moderate moderate modulating Neuropsychiatric NorAD noradrenergic observation outcome participant pathological change pathological changes pathway Pathways Placebo placebo group placebo-controlled Primary outcome randomised receive receptor Regulation secondary Secondary outcomes Study protocol Symptom symptomatic synergistic synergistic effect Test the placebo group thought Treatment treatment group Trial
[DOI] 10.1186/s13063-022-06190-3 PMC 바로가기 [Article Type] Article